HOME >> MEDICINE >> NEWS
Discovery may prevent life-threatening wasting disease in patients with chronic kidney disease

Researchers at Oregon Health & Science University's Doernbecher Children's Hospital have uncovered a unique therapeutic strategy to combat cachexia -- severe malnutrition and physical wasting away -- in children and adults with chronic kidney disease (CKD). The study is published in the June issue of the Journal of Clinical Investigation.

Although the exact cause of cachexia -- a common life-threatening complication of CKD, cancer, AIDS and heart failure patients -- is unknown, Doernbecher researchers found elevated levels of leptin, a hormone that is produced by fat cells and plays a role in weight regulation, may be the cause. Leptin signals through the hypothalamic melanocortin 4 receptor (MC4-R) pathway in the brain, and blocking this pathway may be an important avenue for treatment, they report. The study was conducted in mice.

"Understanding why patients develop cachexia is important because it is associated with very high mortality in patients with chronic kidney disease," said study investigator Robert Mak, M.D., professor of pediatrics in the OHSU School of Medicine and head of pediatric nephrology, Doernbecher Children's Hospital. "Through this research, we have found a novel therapeutic strategy to combat this life-threatening complication of chronic renal disease, which affects more than 10 percent of the population and costs $40 billion each year to treat."

In an accompanying editorial commentary, William Mitch, M.D., past president of the American Society of Nephrology and Edward Randall Distinguished Chairman in Medicine, University of Texas Medical Branch, wrote that this study "provides a quantum increase in our understanding of CKD-associated anorexia."


'"/>

Contact: Tamara Hargens
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
9-Jun-2005


Page: 1

Related medicine news :

1. Discovery of cellular processes which regulate hearts energy supply
2. Discovery in Bubble Boy disease gene therapy
3. Discovery of T-cell traffic control boosts new drug promise
4. Mayo collaboration: Discovery blocks breast cancer growth, stimulates immunity
5. Discovery of a drug anticipation brain signal
6. Discovery of key inflammation mechanism in COPD could lead to new treatments
7. Discovery of a molecular switch could lead to new ways of treating infection, including MRSA
8. Using MRI for diagnosis could help prevent breast cancer progression
9. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation
10. Bioengineering to prevent iron deficiency?
11. Should adult male circumcision be recommended for HIV prevention in the US?

Post Your Comments:
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Potentially illness-causing E. coli ... at farmers markets, according to a new study. ... vendors from 13 farmers markets in Los Angeles and ... Out of almost 150 samples tested, 24 percent were ... salmonella, according to the researchers. Both types of ...
(Date:12/19/2014)... News) -- Older adults who have lost all their teeth ... who still have at least some of their teeth, a ... loss could provide an early warning of increased risk of ... said. However, the findings don,t prove that tooth loss ... more than 3,100 participants 60 and older. People with no ...
(Date:12/19/2014)... LENEXA, Kan. (PRWEB) December 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for Estes Park Medical Center in Estes Park, Colo. ... B. E. Smith has recently placed more than 900 ... Center (EPMC) is a 25-bed, not-for-profit critical access hospital ...
(Date:12/19/2014)... December 19, 2014 Hands On Mobile Spa, ... available. The Spa On Wheels has been transformed into a ... the outside world seems to disappear. The Virtual Tour showcases ... facials, spa parties, corporate events and more. , The Virtual ... On Wheels which is actually an overhauled Winnebago. Marla Kaplan-Pelle, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... the diagnostic, personalized medicine, healthcare information technology, and ... the position of Chief Operating Officer. The announcement ... Partners, marked by a strengthened presence in Boston ... , "Leslie lives and breathes the client experience," ...
Breaking Medicine News(10 mins):Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
(Date:12/17/2014)... 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Office (USPTO) has issued a key patent covering ... vaccine targeting six tumor antigens that are commonly ... No. 8,871,211, which issued October 28, 2014, include ... dendritic cell composition comprising peptide epitopes of the ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced completion of enrollment in its first ... the 3-month observations confirmed the 1-month findings that ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
Cached News: